21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
21:55 , Jun 27, 2018 |  BC Extra  |  Clinical News

Lynparza meets in first-line ovarian cancer

AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib as a first-line maintenance therapy improved progression-free survival (PFS) vs. placebo in patients with BRCA-mutated advanced ovarian cancer, meeting the primary...
00:25 , Jun 16, 2018 |  BioCentury  |  Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

MEI's ME-344 inhibits tumor cell proliferation in breast cancer trial

MEI Pharma Inc. (NASDAQ:MEIP) said ME-344 plus Avastin bevacizumab led to greater inhibition of tumor cell proliferation compared with placebo plus Avastin as measured by the mean reduction in antigen KI-67 (MKI67; Ki-67) expression in...
18:09 , Jun 1, 2018 |  BC Week In Review  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million on May 15 in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were new investor Ruihua...
18:06 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genentech's Tecentriq meets in third Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage...
18:03 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genentech reports detailed OS data for Tecentriq combo in first-line non-squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported additional survival data from the Phase III IMpower150 trial evaluating Tecentriq atezolizumab in 1,202 chemotherapy-naïve patients with advanced stage IV non-squamous non-small cell lung cancer (NSCLC)....
16:45 , May 30, 2018 |  BC Extra  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were Ruihua Investment, existing investor Milestone Capital...
15:07 , May 29, 2018 |  BC Extra  |  Clinical News

Genentech's Tecentriq meets in third Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage...
17:03 , May 25, 2018 |  BC Week In Review  |  Clinical News

ImmunoGen reports updated Phase Ib/II data for ovarian cancer candidate

ImmunoGen Inc. (NASDAQ:IMGN) reported updated data from the Phase Ib/II FORWARD II trial evaluating mirvetuximab soravtansine (IMGN853) to treat folate receptor 1 (FOLR1; FR-alpha)-positive, platinum-resistant epithelial ovarian cancer. The data were released in an abstract...